ChromaDex In Full Color, TCON On Fast Track, FDA's Glad Tidings For GLYC

(RTTNews) - ChromaDex Corp. (CDXC.OB) reported stellar revenue growth for the first quarter ended April 4, 2015, which marks the fourth consecutive period of record revenues.

The revenue in Q1, 2015 was $5.3 million, an increase of 71% compared to $3.1 million for the three months ended March 29, 2014 ("Q1 2014"), and a sequential increase of 24% compared to Q4 2014.

The company's net loss attributable to common stock holders for Q1 2015 shrunk to $1.0 million or $0.01 per share from $1.8 million or $0.02 per share for Q1 2014.

CDXC.OB closed Thursday's trading at $1.32, up 0.76%.

Evoke Pharma Inc. (EVOK) expects its phase III clinical trial of EVK-001, a metoclopramide nasal spray, for diabetic gastroparesis in women to be fully enrolled in the fourth quarter of this year.

The company ended March 31, 2015, with cash of approximately $11.7 million.

EVOK closed Thursday's trading at $5.92, down 2.31%.

GlycoMimetics Inc.'s (GLYC) investigational drug GMI-1271 has been granted Orphan Drug designation for treatment of patients with acute myeloid leukemia.

The company is currently recruiting patients in a phase 1/2, open-label multicenter study to evaluate GMI-1271 in combination with chemotherapy in adult patients with AML; a phase 1 study in healthy volunteers was completed last year.

GLYC closed Thursday's trading at $8.52, up 4.03%.

Shares of TRACON Pharmaceuticals (TCON) were up more than 10% in extended trading on Thursday following the receipt of the FDA's Fast Track designation for the company's TRC105 in patients with advanced renal cell carcinoma (RCC) that have progressed following treatment with one inhibitor of the VEGF pathway in combination with standard dose Inlyta.

A phase II study combining TRC105 and Inlyta in RCC is underway. TRC105 is being explored in other indications as well, and a phase 2 study combining TRC105 and Votrient in soft tissue sarcoma, and a single patient phase 2 study combining TRC105 and Avastin in a patient with choriocarcinoma are also ongoing.

TCON closed Thursday's trading at $10.86, down 3.21%. In after-hours, the stock was up 10.59% to $12.01.

VBL Therapeutics (VBLT) soared more than 57% on Thursday as the company is all set to present positive interim data from the ongoing phase 1/2 clinical trial of lead product candidate, VB-111, for the treatment of platinum-resistant Müllerian cancer on May 30, 2015.

In March of this year, the company announced interim results from its ongoing phase 2 study of VB-111 in patients with recurrent glioblastoma, which demonstrated a statistically significant improvement in overall survival in patients treated with VB-111 followed by VB-111 in combination with bevacizumab (Avastin) upon disease progression, compared to patients treated with VB-111 followed by bevacizumab alone upon disease progression.

VBL expects to initiate a pivotal phase 3 study of VB-111 in recurrent glioblastoma under a Special Protocol Assessment with the FDA in mid-2015.

VBLT closed Thursday's trading 57.84% higher at $6.44.